AbbVie announced that the European Commission (EC) has approved Rinvoq (upadacitinib?, 15 mg), an oral, once daily selective and reversible JAK inhibitor for the treatment of adults with active psoriatic arthritis (PsA) and active ankylosing spondylitis (AS).
AbbVie announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of Rinvoq (upadacitinib, 15 mg), an oral, once daily selective and reversible JAK inhibitor, for the expanded use in two additional rheumatic indications: the treatment of adult patients with active psoriatic arthritis and adult patients with active ankylosing spondylitis.
Japan’s Ministry of Health, Labor and Welfare (MHLW) approved label expansion for AbbVie’s JAK inhibitor Rinvoq (upadacitinib).
UCB, a global biopharmaceutical company, announced that the European Commission (EC) has granted marketing authorisation for Bimzelx(bimekizumab) for the treatment of adults with active psoriatic arthritis (PsA) and adults with active axial spondyloarthritis (axSpA) including non-radiographic axSpA (nr-axSpA) and ankylosing spondylitis (AS), also known as radiographic axSpA
Celltrion USA announced that the FDA has approved Yuflyma (adalimumab-aaty), a high-concentration (100mg/mL) and citrate-free formulation of Humira (adalimumab) biosimilar.
Novartis announces key biosimilar trials in ankylosing spondylitis and psoriatic arthritis.
Containing relevant Learning Zones, guidelines, trials and news.
UCB, a global biopharmaceutical company, announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Bimzelx (bimekizumab) for the treatment of adults with psoriatic arthritis (PsA), non-radiographic axSpA (nr-axSpA) and ankylosing spondylitis (AS) who are not sufficiently responding to existing treatments
Objective: To assess rates of cardiovascular, autoimmune, infectious and other conditions in patients with psoriasis or psoriatic arthritis (PSA).
UCB Canada Inc. is pleased to announce that Bimzelx (bimekizumab injection) has received authorization from Health Canada for two new indications. On February 23, 2024, BImzelx was approved for the treatment of adults with active psoriatic arthritis (PsA) and on March 11, 2024, the therapy also received approval for the treatment of adults with axial spondyloarthritis (axSpA) .